Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection
Status:
Withdrawn
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Hepatitis C virus infection is the most common blood-borne infection in the United States and
is a leading cause of chronic liver disease affecting 130 million people around the world. It
is estimated that 1.6% of the US population may be affected by Hepatitis C infection. The
only recommended treatment that has been approved for your condition is the use of interferon
and ribavirin. In patients with chronic Hepatitis C, there tends to be an accumulation of fat
in the liver. Fatty liver has been associated with failure of treatment.
The accumulation of fat in the liver has been blamed on a particular type of fat called
triglycerides. Fish oil, by reducing a type of fat called VLDL, can lower the triglyceride
concentration by as much as 50 percent or more. This study seeks to determine if the
administration of fish oil along with standard treatment to patients with Hepatitis C will
increase the treatment response rates.
Phase:
N/A
Details
Lead Sponsor:
Truman Medical Center University of Missouri, Kansas City
Collaborators:
Reliant Pharmaceuticals Saint Luke's Health System Foundation Truman Medical Center